Literature DB >> 21992200

Infection rate of spinal cord stimulators after a screening trial period. A 53-month third party follow-up.

Jan Rudiger1, Simon Thomson.   

Abstract

OBJECTIVES: Spinal cord stimulator (SCS) infections are common (2.5-13%) and may cause harm. It is unclear if a screening trial with definitive leads presents an increased infection risk.
METHODS: Eighty-four patients with SCS implantations were reviewed from 2004 to May 2008 with a trial period lasting 1-3 weeks.
RESULTS: During the trial one infection (1.2%) occurred with removal of the SCS leads. Three infections (3.6%) occurred after the second stage and were successfully treated with antibiotics. No full implant was explanted due to infection. The more skilled/experienced operator had a lower infection rate (1.8%) than the less skilled/experienced (13%).
CONCLUSIONS: Our infection rate (4.8%) compared favorably with our previous survey (7.5%). The reduced number of SCS infections is likely to be due to: strict asepsis, double layer hydrocolloid dressing during the trial, prophylactic antibiotics, operator experience, and patient education. Two-stage procedures with extended trials do not seem to increase the incidence of SCS infections.
© 2010 International Neuromodulation Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21992200     DOI: 10.1111/j.1525-1403.2010.00317.x

Source DB:  PubMed          Journal:  Neuromodulation        ISSN: 1094-7159


  6 in total

Review 1.  Spinal Cord Stimulation, MILD Procedure, and Regenerative Medicine, Novel Interventional Nonopioid Therapies in Chronic Pain.

Authors:  Ken P Ehrhardt; Susan M Mothersele; Andrew J Brunk; Jeremy B Green; Mark R Jones; Craig B Billeaud; Alan David Kaye
Journal:  Curr Pain Headache Rep       Date:  2018-03-19

2.  Differences in sacral neuromodulation device infection rates based on preoperative antibiotic selection.

Authors:  Allen M Haraway; J Quentin Clemens; Chang He; Cynthia Stroup; Humphrey O Atiemo; Anne P Cameron
Journal:  Int Urogynecol J       Date:  2013-05-22       Impact factor: 2.894

3.  Root cause analysis of epidural spinal cord stimulator implant infections with resolution after implementation of an improved protocol for surgical placement.

Authors:  Forest W Arnold; Sarah Bishop; David Johnson; LaShawn Scott; Crystal Heishman; Leah Oppy; Tyler Ball; Mayur Sharma; Claudia Angeli; Christie Ferreira; Yangsheng Chen; Susan Harkema; Maxwell Boakye
Journal:  J Infect Prev       Date:  2019-05-02

4.  Antibiotics for Spinal Cord Stimulation Trials and Implants: A Survey Analysis of Practice Patterns.

Authors:  Syena Sarrafpour; Jamal Hasoon; Ivan Urits; Omar Viswanath; Kamran Mahmoudi; Thomas T Simopoulos; Jatinder Gill; Lynn Kohan
Journal:  Anesth Pain Med       Date:  2021-10-30

5.  Postoperative Infections Associated With Prolonged Spinal Cord Stimulation Trial Duration (PROMISE RCT).

Authors:  Richard North; Mehul J Desai; Johan Vangeneugden; Christian Raftopoulos; Tony Van Havenbergh; Marc Deruytter; Jean-Michel Remacle; Jane Shipley; Ye Tan; Mary Jo Johnson; Carine Van den Abeele; Philippe Rigoard
Journal:  Neuromodulation       Date:  2020-04-08

Review 6.  Spinal Cord Stimulation for Neuropathic Pain: Current Trends and Future Applications.

Authors:  Ivano Dones; Vincenzo Levi
Journal:  Brain Sci       Date:  2018-07-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.